(182d) Magneto-Nanosensors for Detecting Novel Protein Interactions and Early Stage Diseases
AIChE Annual Meeting
2016
2016 AIChE Annual Meeting
Sensors
Topical Plenary: Advances in Biosensing (Invited Talks)
Monday, November 14, 2016 - 2:15pm to 2:50pm
The magneto-nanosensors are also well-suited for medical diagnostics of diseases at early stages because they possess attomolar to femtomolar sensitivities for protein biomarkers. The technology platform has been applied to in vitro diagnostics of lung cancer, prostate cancer, liver cancer, autoimmunity, radiation exposure, hepatitis, and cannabis abuse. The magneto-nanosensors are being adapted for point of care settings, mobile health, and global health, and Qualcomm Tricorder XPRIZE competition.
This work is supported in part by National Cancer Institute (NCI) through the Stanford Center for Cancer Nanotechnology Excellence (U54CA151459) and by National Institute of Allergy and Infectious Diseases (NIAID) through the Autoimmunity Center of Excellence (ACE) at Stanford (U19AI110491).